Case report of a monoclonal gammopathy in a patient with chronic hepatitis: Effects of β-IFN treatment

Panminerva Medica

Volumn 38, Issue 3, 1996, Pages 175-178

  Gattoni, A ^a,b   Cecere, A ^a   Romano, C ^a   Di Martino, P ^a   Caiazzo, R ^a   Rippa, A ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b NONE   (Italy)

Author keywords

Interferon, beta; Monoclonal gammopathies

Indexed keywords

ANTIVIRUS AGENT; BETA INTERFERON;

ARTICLE; CASE REPORT; CHRONIC DISEASE; FEMALE; HEPATITIS C; HUMAN; LIVER CIRRHOSIS; MIDDLE AGED; MULTIPLE MYELOMA; PARAPROTEINEMIA; VIROLOGY;

ANTIVIRAL AGENTS; CHRONIC DISEASE; FEMALE; HEPATITIS C; HUMANS; INTERFERON-BETA; LIVER CIRRHOSIS; MIDDLE AGED; MULTIPLE MYELOMA; PARAPROTEINEMIAS;

EID: 0030228187     PISSN: 00310808     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Oken MM, Kyle RA, Kay NE et al. A phase II trial of interferon alpha-2 (IFN alpha-2) in the treatment of resistant multiple myeloma (MM). Proc Am Soc Clin Oncol 1985;4:215.
2. Cooper MR, Fefer A, Thompson J et al. Alpha-2 interferon/melphalan/prednisone in previously untreated patients with multiple myeloma: a phase I-II trial Cancer Treat Rep 1986;70:473
3. Alexanian, Barlogie B, Gutterman J. Interferon treatment for Multiple Myeloma. 5th interferon workshop-IFN therapy in B-cell malignancies. Hannover, 1990, Abstract book p 43.
4. San Miguel JF, Moro M, Blade J et al Combination of Interferon and dexamethasone in refractory multiple myeloma. Hematol Oncol 1990;8:185.
5. Dune BGM, Russel DH, Salmon SE. Reappraisal of plateau phase in myeloma. Lancet 1980;2:65.
6. Creasey AA, Bartholomew IC, Herigan TC. Role of Go-G arrest in the inhibition of tumor cell growth by Interferon. Proc Natl Acad Sci USA 1980;77:1741.
7. Bergsagel DE, Haas RH, Messner HA. Interferon alpha-2b in the treatment of chronic granulocytic leukemia. Semin Oncol 1986;13 (2):29.
8. Brenning G. The in vitro effect of leukocyte alpha interferon on human myeloma cells in a semisolid agar culture system. Scand J Haematol 1985;35:178.
9. Mellstedt H. For the myeloma group of central Sweden. MP versus MP/IFN alpha induction therapy: a randomized trial in multiple myeloma 5th interferon workshop "IFN Therapy in B-Cells Malignancies" - Hannover, 1990, abstract book p. 44.
10. Peest D, Deicher H, Coldewey R et al. Melphalan and prednisone (MP) versus vincristine, BCNU, adriamicin, melphalan and dexamethasone (VBAMD ex) induction chemotherapy and interferon maintenance treatment in multiple myeloma. Current results of a multicenter trial. Onkologie 1990;13:458.
11. Oken MM, Kyle RA, Geripp PR et al. Complete remission (CR) induction with VBMCP + interferon (IFN alpha-2) in multiple myeloma: 3-year follow-up. Proc Am Soc Clin Oncol 1989;8:872.
12. Scheithauer W, Cortelezzi A, Fritz E et al. Combined alpha-2c interferon/VMCP polychemotherapy versus VMPC polychemotherapy as induction therapy of multiple myeloma: a prospective randomized trial J Biol Response Hod 1989;8:109.
13. Mandelli F, Avvisati G, Amadori S et al. Maintenance treatment with recombinant interferon alpha-2b in patients with multiple myeloma responding to conventional induction chemotherapy. N Engl J Med 1990;322:1430.
14. Westin J, Cortelezzi A, Ajort M et al. Interferon therapy during the plateau phase of multiple myeloma: an update of a Swedish multicenter study. 3rd International Workshop on Multiple Myeloma' "From Biology to Therapy". Torino 1991 abstract book p. 113.
15. Billiau A, Bloemmen J, Bogaerts M et al. Interferon therapy in multiple myeloma: failure of human fibroblast interferon administration to affect the course of light chain disease. Eur J Cancer Clin Oncol 1981;17:875-82.
16. Misset JL, Nathe J, Gastiaburu A et al. Treatment of lymphoid neoplasias with interferon I human fibroblastic beta-interferon in malignant gammapathies phase II trial. Anticancer Res 1982;2v:63-6.
17. Quesada JR, Alexanian R, Kurzrock R, Barlogie B, Saks S, Gutterman JU. Recombinant interferon gamma in hairy cell leukemia, multiple myeloma and Waldestrom's macroglobulinemia. Am J Hematol 1988;29:1-4.
18. Salmon SE, Durie BG, Yung L et al. Effects of cloned leukocyte interferon in the human tumor stem cell assay. J Clin Oncol 1983;1:217.
19. Brenning G, Aher A, Nilsso K. Correlation between in vitro and in vivo sensitivity to human leukocyte interferon in patients with multiple myeloma. Scand J Haematol 1985;35:543.
20. Cox EB, Lazlo J, Krown S et al. Phase II study of human lymphoblastoid interferon (alpha-IFN) in the treatment of multiple myeloma. J Biol Resp Mod 1988;7:318.
21. Tanaka H, Tanabe O, Iwato K et al. Sensitive inhibitory effect of interferon-alpha on M protein secretion of human myeloma cells. Blood 1989;74:1718.
22. Montuoro A, De Rosa L, De Blasto A et al. Alpha-2a interferon/melphalan/prednisone versus melphalan/prednisone in previously untreated patients with multiple myeloma. Br J Haematol 1990;76:365.
23. Jernberg-Wiklund H, Pettersson M, Nilsson K. Recombinant interferon-gamma inhibits the growth of IL-6 dependent human multiple myeloma cells lines in vitro. Eur J Haematol 1991;46:231.
24. Grander D, Von Stedingk LV, Von Stedingk M et al. Influence of interferon of antibody production and variability of malignant cells from patients with multiple myeloma. Eur J Haematol 1991;46:17.
25. Alexanian R, Barlogie B, Gutterman J Alpha-interferon combination therapy of resistant myeloma. Am J Clin Oncol 1991;14:188.